Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.
How it described itself
Developing first-in-class immunotherapies to treat autoimmunity and cancer
Developing first-in-class immunotherapies to treat autoimmunity and cancer abcuro the next generation of T cell targeted bio-therapeutics Finding A Cure Starts with Patients SCIENCE TEAM PIPELINE HOW
All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.
How it describes itself
Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.
January 2021 – January 2022 · 2 captures · latest observed messagingDevelopment of immunotherapies for autoimmune diseases and cancer
Development of immunotherapies for autoimmune diseases and cancer Read more about our approach in Fierce Biotech KLRG1 – A Compelling Clinical Target in Immune Modulation Abcuro is a clinical stage bi
9 January 2021 · Development of immunotherapies for autoimmune diseases and cancerarchived page
22 January 2022 · Development of immunotherapies for autoimmune diseases and cancerarchived page
Seen August 2020 · 1 captureDeveloping first-in-class immunotherapies to treat autoimmunity and cancer
Developing first-in-class immunotherapies to treat autoimmunity and cancer abcuro the next generation of T cell targeted bio-therapeutics Finding A Cure Starts with Patients SCIENCE TEAM PIPELINE HOW